Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 11/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.34 |
| ▸ | TCF7 | P36402 | 2/20 | 0.34 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | TCF4 | P15884 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14319234 | 0.90 | CLPP (0.35) | CLPPCTSDBACE1CTNNB1TCF7 | |
| SCHEMBL17572699 | 0.90 | CLPP (0.39) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13773713 | 0.90 | CLPP (0.41) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14319449 | 0.89 | CLPP (0.47) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14504851 | 0.89 | CYP3A4 (0.36) | CYP3A4 | |
| SCHEMBL13774093 | 0.88 | SIGMAR1 (0.39) | CLPPCTNNB1TCF7ALDH1A1 | |
| SCHEMBL14503911 | 0.88 | BACE1 (0.39) | CLPPCTSDBACE1ALDH1A1 | |
| SCHEMBL14309381 | 0.88 | CLPP (0.34) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL14309930 | 0.87 | CLPP (0.39) | CLPPALDH1A1 | |
| SCHEMBL14309433 | 0.87 | CACNA1G (0.41) | CLPPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | CLPP 2188/4885CTSD 1100/4885BACE1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.